Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.
Merck & Co. is close to finalizing a takeover bid for Seagen, with media reports citing an offer in the region of $38bn.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
